Aptose Biosciences Inc.
APS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.15% | 46.11% | 47.58% | 54.78% | 50.34% |
| Total Depreciation and Amortization | -31.25% | -91.13% | -94.91% | -95.05% | -93.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 93.58% | -54.78% | -78.92% | -79.94% | -75.80% |
| Change in Net Operating Assets | 114.86% | -66.52% | -2,080.30% | -479.74% | -587.60% |
| Cash from Operations | 38.88% | 34.88% | 27.22% | 40.06% | 19.33% |
| Capital Expenditure | -- | -- | -- | 82.76% | 82.76% |
| Sale of Property, Plant, and Equipment | -- | -72.22% | -72.22% | 2,100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -81.84% | -100.00% |
| Cash from Investing | -- | -100.00% | -100.00% | -81.64% | -99.82% |
| Total Debt Issued | 86.50% | 3.50% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.46% | -57.58% | -66.77% | -33.62% | 239.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 193.41% | 190.70% | -- | -- |
| Cash from Financing | -42.00% | -34.88% | -9.91% | 19.72% | 383.56% |
| Foreign Exchange rate Adjustments | -- | 100.00% | -- | 150.00% | -100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.59% | 18.47% | -9,945.71% | 83.11% | 90.82% |